The estimated Net Worth of Matthew Pauls is at least $6.02 Milione dollars as of 28 December 2023. Mr. Pauls owns over 84,000 units of Savara Inc stock worth over $5,627,552 and over the last 12 years he sold SVRA stock worth over $395,640. In addition, he makes $0 as Chairman of the Board e Interim Chief Executive Officer at Savara Inc.
Sign up
Mr. Pauls SVRA stock SEC Form 4 insiders trading
Matthew has made over 10 trades of the Savara Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 84,000 units of SVRA stock worth $395,640 on 28 December 2023.
The largest trade he's ever made was selling 84,000 units of Savara Inc stock on 28 December 2023 worth over $395,640. On average, Matthew trades about 8,904 units every 90 days since 2013. As of 28 December 2023 he still owns at least 1,302,674 units of Savara Inc stock.
You can see the complete history of Mr. Pauls stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Pauls biography
Matthew Pauls J.D. serves as Chairman of the Board, Interim Chief Executive Officer of the Company. Mr. Pauls currently is the founder of Spartan Biopharma Insights, LLC, providing strategic advisement to institutional investors, c-suite executives, board directors, et al on investment thesis assessment, capitalization strategy, mergers and acquisitions, clinical execution, and commercialization. Mr. Pauls also serves on the board of directors of Zyla Life Sciences (previously Egalet Corporation) (OTCQX: ZCOR), a commercial-stage life sciences company with a portfolio of medicines for pain and inflammation. Previously, Mr. Pauls served as President and Chief Executive Officer of Strongbridge Biopharma plc (NASDAQ: SBBP), a biopharmaceutical company focused on therapies that target rare diseases from August 2014 to November 2019. He also served as a member of the board of directors of Strongbridge from September 2015 to November 2019. From April 2013 to August 2014, Mr. Pauls was Chief Commercial Officer of Insmed, Inc. (NASDAQ: INSM), a publicly traded global biopharmaceutical company focused on rare diseases. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, a global specialty biopharmaceutical company, from 2007 to April 2013, most recently as Senior Vice President, Head of Global Commercial Operations from May 2012 to April 2013. Earlier in his career, from 1997 to 2007, Mr. Pauls held senior positions at Bristol-Myers Squibb in Brand Management and Payor Marketing and at Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.
How old is Matthew Pauls?
Matthew Pauls is 50, he's been the Chairman of the Board e Interim Chief Executive Officer of Savara Inc since 2020. There are 10 older and 1 younger executives at Savara Inc. The oldest executive at Savara Inc is Richard Hawkins, 71, who is the Independent Director.
What's Matthew Pauls's mailing address?
Matthew's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.
Insiders trading at Savara Inc
Over the last 8 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.
What does Savara Inc do?
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
What does Savara Inc's logo look like?
Complete history of Mr. Pauls stock trades at Insmed Inc, Savara Inc, Soleno Therapeutics Inc e Strongbridge Biopharma plc
Savara Inc executives and stock owners
Savara Inc executives and other stock owners filed with the SEC include:
-
Dr. Badrul A. Chowdhury M.D., Ph.D.,
Chief Medical Officer -
David Lowrance,
Chief Financial Officer, Secretary -
David L. Lowrance,
CFO & Sec. -
Ricky Sun,
Independent Director -
Annigje van Es-Johansson,
Independent Director -
Badrul Chowdhury,
Chief Medical Officer -
Anne Erickson,
IR Contact Officer -
David Ramsay,
Independent Director -
Matthew Pauls,
Chairman of the Board, Interim Chief Executive Officer -
Joseph McCracken,
Independent Director -
Richard Hawkins,
Independent Director -
Nevan Elam,
Independent Director -
Dr. Peter Clarke Ph.D.,
Exec. VP of Global Technical Operations -
Charles LaPree,
Sr. VP of Global Regulatory Affairs & Quality Assurance -
Brian Maurer,
Head of Clinical Operations -
Dr. Dhaval Desai M.D.,
Head of Clinical Devel. -
Kate McCabe,
Sr. VP of Legal Affairs -
Robert N Neville,
Chief Executive Officer -
Yuri Pikover,
Director -
Jaakko Taneli Jouhikainen,
See Remarks -
Es Johansson An Van,
Director -
Forest Baskett,
10% owner -
Equity Opportunities 17, Ll...,
-
Rick Yang,
10% owner -
Paul Edward Walker,
10% owner -
Scott D Sandell,
10% owner -
Edward T Mathers,
10% owner -
Mohamad Makhzoumi,
10% owner -
Carmen Chang,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ali Behbahani,
10% owner -
Raymond Dennis Pratt,
Chief Medical Officer -
Robert Matthew Lutz,
Chief Operating Officer